When all eligible studies were pooled into one dataset for the meta-analysis, we found no statistical association between the ERCC5 Asp1104His polymorphism and overall cancer risk under the recessive genetic models: His/His vs. Asp/Asp: OR = 0.99, 95% CI: 0.92–1.06 or His/His vs. Asp/His + Asp/Asp: OR = 0.98, 95% CI: 0.93–1.03. Here, ERCC5 is linked to cancer.